Shares jumped after Wedbush raised its target and B. Riley initiated coverage, pointing to strong early launch momentum for ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to ...

Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

Eli Lilly is well on its way to the trillion-dollar club. The stock price is up 30% so far this year; with a total ...

Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) ...

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

After starting the day with a sharp drop of 1.3%, the S&P 500 erased all of it and then meandered up and down before ...

The Food and Drug Administration shouldn’t be in the news if it’s doing its job right. By that measure the FDA is failing in spectacular fashion. The agency this week is making news for all of the ...